9th Sep 2019 07:00
genedrive plc
("genedrive" or the "Company")
Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.
For further details please contact:
genedrive plc | www.genedriveplc.com | |
David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 | |
Peel Hunt LLP | +44 (0)20 7418 8900 | |
James Steel / Oliver Jackson | ||
Stanford Capital Partners Limited | +44 (0)20 3815 8880 | |
Patrick Claridge / John Howes | ||
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or [email protected] | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).
Further details can be found at: www.genedriveplc.com and www.genedrive.com.
Related Shares:
Genedrive